Ongoing Surveillance for Confirmed Phantom hCG
Once phantom hCG is confirmed with normal tumor marker hCG, no ongoing surveillance is required—the patient can be discharged from hCG monitoring. 1
Understanding Phantom hCG
Phantom hCG represents assay interference (typically from heterophilic antibodies) rather than true circulating hCG. The key diagnostic feature is that serum hCG remains positive while urine hCG is negative, since immunoglobulins causing the interference are not filtered into urine 2, 1, 3. When tumor marker hCG testing (using a different assay or with blocking agents) returns normal, this confirms the diagnosis.
Why No Surveillance is Needed
The critical distinction is that phantom hCG is not a disease state—it's a laboratory artifact. Unlike true gestational trophoblastic disease or malignancy where hCG reflects actual pathology requiring monitoring, phantom hCG has no clinical significance once confirmed 1, 3.
The 2026 ACOG Clinical Consensus explicitly addresses this scenario: false-positive hCG due to assay interference occurs in approximately 1 in 1,000 to 1 in 10,000 serum tests 1. Once identified through:
- Negative urine hCG
- Normal tumor marker hCG (different assay)
- Exclusion of pregnancy, gestational trophoblastic disease, and germ cell tumors
No further monitoring is indicated 1.
Important Caveats
Ensure Complete Diagnostic Workup Was Performed
Before discontinuing surveillance, confirm that the evaluation excluded:
- Pregnancy (ultrasound, urine hCG)
- Pituitary hCG (check FSH levels, especially in perimenopausal/menopausal patients where hCG cutoff should be <14 IU/L rather than <5 IU/L) 2, 1
- Renal failure (kidney function tests)
- Familial hCG syndrome (rare; requires parental testing if suspected) 2
- Gestational trophoblastic disease or germ cell tumors (imaging, clinical history)
Document the Diagnosis Clearly
Record in the medical record:
- The discordant serum (positive) vs. urine (negative) hCG results
- Normal tumor marker hCG result using alternative assay
- Exclusion of other causes of true-positive hCG
- Clear statement that this represents phantom hCG/assay interference
Patient Counseling
Inform the patient that:
- This is a laboratory phenomenon, not a medical condition
- No treatment or ongoing monitoring is needed
- Future hCG testing (e.g., for pregnancy) should note the history of heterophilic antibody interference
- Different assay methods or urine testing should be used for future pregnancy testing if needed
Contrast with True Low-Level hCG
This recommendation differs dramatically from persistent true low-level hCG after gestational trophoblastic disease, which requires intensive surveillance. For comparison, patients with true persistent low-level hCG after GTD need monitoring until FIGO criteria for GTN are met or hCG normalizes 2, 4, 5. However, once phantom hCG is confirmed, this concern is eliminated.